Please check your internet connection and try again.
# Durveqtix (fidanacogene elaparvovec-dzkt)
## Overview
Durveqtix is an adeno-associated virus vector-based gene therapy designed to deliver a functional copy of the *F9* gene to liver cells. It enables sustained endogenous production of Factor IX (FIX) in patients with hemophilia B, potentially eliminating the need for routine prophylactic factor replacement.
## Primary Indications
Treatment of adults (≥18 years) with moderate to severe hemophilia B (congenital Factor IX deficiency) who currently use Factor IX prophylactic therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes.
## Adult Dosing
The recommended dose is $5 \times 10^{11}$ vector genomes per kilogram ($vg/kg$) of body weight, administered as a single-dose intravenous infusion.
## Pediatric Dosing
Safety and effectiveness have not been established in pediatric patients (under 18 years of age).
## Dose Adjustments
* **Renal/Hepatic Impairment:** No formal clinical studies have been conducted. Use caution in patients with pre-existing hepatic impairment, as viral vector clearance and transgene expression may be affected.
* **Adjustment:** Dose is fixed based on weight; no dose-escalation or repeat-dosing protocols exist.
## Contraindications
* Hypersensitivity to the active substance or any excipient.
* Active infection (acute or chronic) that may interfere with vector transduction or increase the risk of inflammatory complications.
## Adverse Effects
* **Most Common (>10%):** Transaminase elevations (ALT/AST), infusion-related reactions, nausea, fatigue, headache, and increased creatine kinase.
* **Serious:** Potential for hepatotoxicity requiring corticosteroid intervention. There is a theoretical long-term risk of genotoxicity due to vector integration.
## Key Drug Interactions
* **Corticosteroids:** Concomitant use of systemic corticosteroids or other immunosuppressants is required for the management of potential immune-mediated transaminitis.
* **Hepatotoxic Agents:** Avoid concomitant use of other drugs known to cause liver injury, as these may complicate the monitoring of liver enzyme elevations post-infusion.
## Monitoring
* **Liver Enzymes:** Monitor ALT levels weekly for at least the first 3–4 months post-infusion to facilitate early detection of immune-mediated hepatotoxicity.
* **Factor IX Activity:** Periodically monitor FIX activity levels to assess sustained therapeutic expression.
* **Bleeding Events:** Monitor for clinical signs of hemorrhage, as factor levels may fluctuate during the induction period.
## Clinical Pearls
* **Immunosuppression:** Almost all patients will require a tapering course of systemic corticosteroids (e.g., prednisone or prednisolone) starting shortly after infusion to preserve transgene expression and manage subclinical immune responses to the viral capsid.
* **Efficacy:** Patients may require continued prophylaxis with Factor IX concentrate for a short period post-infusion until transgene expression levels become therapeutic.
* **Pre-existing Immunity:** Patients should be screened for pre-existing antibodies to the AAV-Rh74 capsid; current data suggests low titers may not absolutely preclude treatment, but high titers may limit efficacy.
* **Administration:** It is a one-time, weight-based infusion. Proper handling and sterile technique during preparation are critical.
***
**Educational Disclaimer:** This information is for educational purposes only. Durveqtix is a specialized gene therapy requiring administration in qualified clinical centers. Always verify current prescribing information, institutional protocols, and FDA/EMA-approved labeling before clinical prescribing or administration. Clinicians should consult the full manufacturer’s package insert for complete risk mitigation strategies and patient selection criteria.
